The cost of GLP-1s needs to come way down for benefits to be worth it, study says
While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them economically inefficient under current U.S. healthcare standards, according to a new study published Friday in JAMA Health Forum.Read more... [...]
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
The 6 best Mint alternatives to replace the budgeting app that shut down
It's been almost one year since Intuit shut down the popular budgeting app Mint. I was a Mint user for many years; millions of other users like me enjoyed how easily Mint allowed us to track all [...]
Infrastructure and compute: Enterprises are buying AI compute for speed while flying blind on what it costs
Across 170 enterprises, AI infrastructure has moved decisively into production — two-thirds now run AI workloads live and three in 10 run them at scale — while the ability to account for what that [...]
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]
Weight Watchers files for bankruptcy amid refocus on GLP-1 drugs
WeightWatchers (WW) announced Tuesday that it is filing for bankruptcy in an attempt to crawl out of more than $1 billion in debt. The news comes as the company is amid a refocus on prescribing weight [...]
Anthropic brings Mythos to the masses with Claude Fable 5, its most powerful generally available model ever
Anthropic today launched two new AI models — Claude Fable 5 and Claude Mythos 5 — marking the company’s first broad release of the powerful “Mythos-class” AI capabilities it previously kept [...]